オピオイド治療プログラムにおけるメタドンによるクラトム使用障害の治療
1Chief Science Officer, Community Medical Services (RCS).
Journal of addiction medicine
|February 12, 2026
まとめ
メタドンは,クラトム使用障害 (KUD) を効果的に治療し,良好な耐受性および保持率を示しました. この研究は,ブプレノルフィンが適切でない場合,KUD管理の実行可能な選択肢としてメタドンを支持しています.
科学分野:
- 薬理学 薬理学とは
- 依存症医学 薬物中毒医学
- 毒理学 毒理学 毒理学
背景:
- クラトム (Mitragyna speciosa) とそのアルカロイドは,オピオイドのような依存症と離脱を引き起こす可能性があり,オピオイド使用障害 (OUD) の基準を満たしています.
- ブプレノルフィンはクラトム使用障害 (KUD) のために文書化されているが,メタドンの臨床経験は稀である.
研究 の 目的:
- KUD患者の治療におけるメタドンの有効性と安全性を評価する.
- KUD患者コホートにおけるメタドンの耐受性および保持率を評価する.
主な方法:
- 複数のオピオイド治療プログラム (OTP) でメタドンで治療されたKUD患者の14人の遡及レビュー.
- 人口統計,メタドン用量,尿毒性データの分析.
- 試験期間:2024年1月 - 2025年10月 試験期間:2024年1月 - 2025年10月 試験期間:2025年10月 試験期間:2024年1月 - 2025年10月 試験期間:2025年10月 試験期間:2024年1月 - 2025年10月 試験期間:2025年10月 試験期間
主要な成果:
- この研究では,平均年齢が36.8歳であった14人の患者が参加し,71%が男性でした.
- 64%がクラトムと7-ヒドロキシミトラギニン (7-OH) の同時使用を報告した.
- メタドン初投与量は平均で27.5mg,最大投与量は平均で98.6mgでした.患者の93%が治療を続け,有害事象は報告されませんでした.
結論:
- メタドンはよく耐えており,KUD患者の安定化に効果的でした.
- メタドンは,特にブプレノルフィンが不適当である場合,KUDの実行可能な治療の代替手段を表しています.
関連する概念動画
Treatment Strategies for Psychological Disorders
797
Treatment approaches for psychological disorders fall into three main categories: psychological, biological, and sociocultural. Each approach targets different aspects of mental health, requiring varying levels of education and training.
Psychological therapies focus on modifying emotions, thoughts, and behaviors through talking, interpreting, listening, rewarding, challenging, and modeling. Clinical psychologists, counselors, and social workers commonly practice psychotherapy. Clinical...
Psychological therapies focus on modifying emotions, thoughts, and behaviors through talking, interpreting, listening, rewarding, challenging, and modeling. Clinical psychologists, counselors, and social workers commonly practice psychotherapy. Clinical...
797
Open Angle Glaucoma: Treatment
1.0K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.0K
Treatment Resistant Cancers
3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Opioid Analgesics: Synthetic and Semisynthetic Opioids
1.1K
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
1.1K
Parkinson's Disease: Treatment
1.2K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.2K
Alzheimer's Disease: Treatment
976
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
976


